An Expert’s Guide To Switching In Germany, Part 1: Navigating The Reclassification Process
Executive Summary
Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, talks exclusively to HBW Insight about prescription-to-OTC switching in Germany and the association’s efforts to improve this process.
You may also be interested in...
Sandoz' Hexal Wins Landmark German Case Over Desloratadine Switch
Sandoz, through its Hexal subsidiary, has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs.
Novartis Wins Landmark Case Against German Government Over Desloratadine Switch
Generics giant Novartis through its Hexal subsidiary has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs.
German Industry Wants To Simplify 'Complicated' Switch Process
The German Medicines Manufacturers´ Association